Catherine Palmer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Catherine Palmer has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Brent S. Inouye
School of Pharmacy & Health Professions, Creighton University, Omaha, NE 68178, USA
2 shared publications - Christopher J. Destache
Schools of Medicine and Pharmacy & Health Professions, Creighton University, Omaha, NE, USA
2 shared publications - Dorothy Kenny
School of Medicine, Creighton University, Omaha, NE 68178, USA
2 shared publications - Elton Jeffrey North
Department of Pharmacy Sciences, School of Pharmacy and Health Professions, Creighton University, Omaha, NE 68178, USA
2 shared publications - Manasa Velagapudi
School of Medicine, Creighton University, Omaha, NE 68178, USA
2 shared publications - Mariaelena Roman Sotelo
School of Pharmacy & Health Professions, Creighton University, Omaha, NE 68178, USA
2 shared publications
Latest Publications
- Open Access
- 30 October 2024
- Published by MDPI AG in Antibiotics
- Vol. 13 (11) , 1024
Impact of Extracorporeal Membrane Oxygenation (ECMO) on Serum Concentrations of Cefepime
ECMO is becoming widely used as a life-saving measure for critically ill patients. However, there is limited data on pharmacokinetics and the dosing of beta-lactam antibiotics in ECMO. In this study, we evaluated the serum concentrations of cefepime in patients on ECMO to determine the impact of ECMO circuitry and to guide therapeutic dosing. Methods: Patients 19 years or older admitted to the ICU, treated with ECMO and beta-lactam antibiotics for presumed or documented infection, were enrolled. Three blood samples (peak, midpoint, trough) were obtained before ECMO (pre-ECMO) and during ECMO (intra-ECMO) at a steady state. Results: Eight patients met inclusion criteria; six received cefepime. All patients were male. Average ± SD age was 45.8 ± 14.7. Four patients received ECMO for severe SARS-CoV-2 infection, and one each for Pneumocystis pneumonia and influenza A infection. Mean ± SD APACHE II and SOFA scores prior to ECMO were 24.6 ± 7.1 and 11.0 ± 3.9, respectively. All but one of the patients received venovenous (VV) ECMO. Cefepime 1 g every 6 h intravenously over 2 min was administered to all patients before and during ECMO. Cefepime concentrations were fit to non-compartment analysis (NCA) and area under the serum concentration–time curve averaged ± SE 211.9 ± 29.6 pre-ECMO and 329.6 ± 32.3 mg*h/L intra-ECMO, p = 0.023. No patients displayed signs of cefepime neurotoxicity. Patients received ECMO for 43.1± 30 days. All patients expired. Cefepime dosed at 1 g every 6 h intravenously appears to achieve therapeutic levels for critically ill patients on ECMO.
- 30 October 2024
- Published by MDPI AG in Antibiotics
- Vol. 13 (11) , 1024
Open AccessImpact of Extracorporeal Membrane Oxygenation (ECMO) on Serum Concentrations of Cefepime
ECMO is becoming widely used as a life-saving measure for critically ill patients. However, there is limited data on pharmacokinetics and the dosing of beta-lactam antibiotics in ECMO. In this study, we evaluated the serum concentrations of cefepime in patients on ECMO to determine the impact of ECMO circuitry and to guide therapeutic dosing. Methods: Patients 19 years or older admitted to the ICU, treated with ECMO and beta-lactam antibiotics for presumed or documented infection, were enrolled. Three blood samples (peak, midpoint, trough) were obtained before ECMO (pre-ECMO) and during ECMO (intra-ECMO) at a steady state. Results: Eight patients met inclusion criteria; six received cefepime. All patients were male. Average ± SD age was 45.8 ± 14.7. Four patients received ECMO for severe SARS-CoV-2 infection, and one each for Pneumocystis pneumonia and influenza A infection. Mean ± SD APACHE II and SOFA scores prior to ECMO were 24.6 ± 7.1 and 11.0 ± 3.9, respectively. All but one of the patients received venovenous (VV) ECMO. Cefepime 1 g every 6 h intravenously over 2 min was administered to all patients before and during ECMO. Cefepime concentrations were fit to non-compartment analysis (NCA) and area under the serum concentration–time curve averaged ± SE 211.9 ± 29.6 pre-ECMO and 329.6 ± 32.3 mg*h/L intra-ECMO, p = 0.023. No patients displayed signs of cefepime neurotoxicity. Patients received ECMO for 43.1± 30 days. All patients expired. Cefepime dosed at 1 g every 6 h intravenously appears to achieve therapeutic levels for critically ill patients on ECMO.
- Open Access
- 21 October 2024
- Published by MDPI AG in Preprints.org
Impact of Extra-Corporeal Membrane Oxygenation (ECMO) on Serum Concentrations of Cefepime
ECMO is becoming widely used as a life saving measure for critically ill patients. However, there is limited data on pharmacokinetics and dosing of beta-lactam antibiotics in ECMO. In this study, we evaluated the serum concentrations of cefepime in patients on ECMO to determine the impact of ECMO circuitry and to guide therapeutic dosing. Methods: Patients 19 years or older admitted to the ICU, treated with ECMO and beta-lactam antibiotics for presumed or docu-mented infection, were enrolled. Three blood samples (peak, midpoint, trough) were obtained before ECMO (pre-ECMO) and during ECMO (intra-ECMO) at steady state. Results: Eight pa-tients met inclusion criteria; six received cefepime. All patients were male. Average ±SD age was 45.8±14.7. Four patients received ECMO for severe SARS-CoV-2 infection, and one each for Pneumocystis pneumonia and influenza A infection. Mean ±SD APACHE II and SOFA scores prior to ECMO were 24.6±7.1 and 11.0±3.9, respectively. All but one received venovenous (VV) ECMO. Cefepime 1 gram every 6 hours intravenously over 2 minutes was administered to all patients before and during ECMO. Cefepime concentrations were fit to a one-compartment model and area under the serum-concentration time curve averaged ± SE 204.6 ± 51.2 pre-ECMO and 344.7 ± 51.5 mg*h/L intra-ECMO, p>0.05. No patients displayed signs of cefepime neurotoxi-city. Patients received ECMO for 43.1± 30 days. All patients expired. Cefepime dosed at 1 gram every 6 hours intravenously appears to achieve therapeutic levels for critically ill patients on ECMO.
- 21 October 2024
- Published by MDPI AG in Preprints.org
Open AccessImpact of Extra-Corporeal Membrane Oxygenation (ECMO) on Serum Concentrations of Cefepime
ECMO is becoming widely used as a life saving measure for critically ill patients. However, there is limited data on pharmacokinetics and dosing of beta-lactam antibiotics in ECMO. In this study, we evaluated the serum concentrations of cefepime in patients on ECMO to determine the impact of ECMO circuitry and to guide therapeutic dosing. Methods: Patients 19 years or older admitted to the ICU, treated with ECMO and beta-lactam antibiotics for presumed or docu-mented infection, were enrolled. Three blood samples (peak, midpoint, trough) were obtained before ECMO (pre-ECMO) and during ECMO (intra-ECMO) at steady state. Results: Eight pa-tients met inclusion criteria; six received cefepime. All patients were male. Average ±SD age was 45.8±14.7. Four patients received ECMO for severe SARS-CoV-2 infection, and one each for Pneumocystis pneumonia and influenza A infection. Mean ±SD APACHE II and SOFA scores prior to ECMO were 24.6±7.1 and 11.0±3.9, respectively. All but one received venovenous (VV) ECMO. Cefepime 1 gram every 6 hours intravenously over 2 minutes was administered to all patients before and during ECMO. Cefepime concentrations were fit to a one-compartment model and area under the serum-concentration time curve averaged ± SE 204.6 ± 51.2 pre-ECMO and 344.7 ± 51.5 mg*h/L intra-ECMO, p>0.05. No patients displayed signs of cefepime neurotoxi-city. Patients received ECMO for 43.1± 30 days. All patients expired. Cefepime dosed at 1 gram every 6 hours intravenously appears to achieve therapeutic levels for critically ill patients on ECMO.